The Peptide Addict
COMPARISON

Semaglutide vs Tirzepatide vs Retatrutide

The three most-discussed GLP-1-class compounds, compared on evidence, safety, access, cost, and what the market conversation routinely gets wrong.

Quick verdict: Semaglutide has the deepest real-world track record and the clearest access path. Tirzepatide is more effective for most users and has rapidly accumulating clinical data. Retatrutide is the most powerful in early trials but still in development — and its popularity is running ahead of its evidence. All three belong in the "this actually works" category, which is rare in peptides. The differences are real and they matter.

Best fit by goal and context

Semaglutide. The default first choice for most people. Longest real-world usage, widest availability, most predictable side effect profile, most primary-care familiarity.

Tirzepatide. The better choice when weight loss is the primary goal and access is possible. Dual GIP/GLP-1 mechanism produces larger weight loss on average in head-to-head trials.

Retatrutide. Not yet FDA-approved. Triple-agonist (GLP-1 + GIP + glucagon). Most impressive weight-loss numbers in early trials. Should currently be thought of as "a drug in late clinical development," not "a drug you can responsibly use."

Evidence comparison

Semaglutide has the strongest evidence base of any drug in this category.

  • STEP trials (obesity): sustained 15%+ weight loss over 68 weeks
  • SUSTAIN trials (type 2 diabetes): strong HbA1c reductions across populations
  • SELECT trial: cardiovascular benefit in overweight adults with established CV disease
  • Years of post-market data across millions of patients

Tirzepatide is newer but clinically robust.

  • SURPASS program (diabetes): superior HbA1c reduction vs other standard-of-care agents
  • SURMOUNT program (obesity): weight loss outcomes exceeding semaglutide in direct comparisons, with some trial arms showing 20%+ reduction
  • Growing real-world evidence base

Retatrutide is early but striking.

  • Phase 2 obesity trial: average 24% weight loss at 48 weeks at the highest dose
  • Phase 3 trials underway as of 2025
  • Not yet approved for any indication

The relevant distinction: semaglutide and tirzepatide are evidence-backed choices you can make with your prescriber. Retatrutide is an investigational drug whose evidence base is actively being built. Using it off-trial means accepting unknown unknowns that don't exist with the approved options.

Safety comparison

All three share a similar safety framework because they act on overlapping pathways.

Common to all three: - GI effects (nausea, vomiting, constipation, diarrhea) — most intense during dose escalation, usually settling with time - Risk of pancreatitis — rare but documented - Gallbladder events at higher rates than placebo - Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2

Semaglutide has the longest real-world safety signal. The profile is well-characterized.

Tirzepatide shows similar GI effects, possibly slightly more intense during titration at higher doses. Cardiovascular safety signal appears favorable but the long-term dataset is shorter.

Retatrutide adds a glucagon receptor agonist effect. In trials this has been associated with slightly higher heart rate and some metabolic complexity. The longer-term safety profile is still being established.

The safety rule that matters most: dose escalation should happen slowly, and side effects during escalation are a normal experience rather than a reason to abandon the class.

This is where the three diverge sharply.

Semaglutide is FDA-approved as Ozempic (diabetes) and Wegovy (weight management). Access through insurance varies wildly. Compounded semaglutide availability has shifted multiple times as shortage status changed. As of 2026, the compounding landscape is significantly narrower than it was in 2023–2024.

Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). Similar insurance story. Similar compounding trajectory. Access has improved through 2025 as supply stabilized.

Retatrutide is not approved. Period. The only legitimate access path as of 2026 is enrollment in a clinical trial. Anything labeled "retatrutide" outside a trial comes from a research-chemical vendor with no regulatory oversight — no identity verification, no purity guarantees, no dosing precision.

The gray-market retatrutide market is growing fast and it is one of the clearest examples of a hype gap in the current peptide landscape. People are buying and self-administering an investigational drug based on Phase 2 trial results. We think that deserves to be stated clearly rather than buried.

Cost and complexity comparison

Semaglutide and tirzepatide — when accessed through insurance and covered, cost varies from manageable to significant copays. Cash pay without insurance runs into the hundreds to thousands per month depending on dose and source. Compounded versions (where still available) are cheaper but come with their own quality-control questions.

Retatrutide — no legal retail path. "Research chemical" pricing is variable and meaningless as a cost anchor, because you're not buying the same product as the one in the Phase 2 trial.

All three require injection. All three require dose escalation. All three benefit significantly from clinical supervision — for dose adjustment, side effect management, and medical monitoring of the metabolic changes they produce.

Key tradeoffs

Semaglutide: Safest bet for a first-time user. Best-known profile. Second-most-effective of the three for weight loss.

Tirzepatide: More effective than semaglutide in head-to-head trials. Slightly newer, so less long-tail safety data. Approved and accessible.

Retatrutide: Most effective on early data. Not approved. Using it today means accepting the risks of an investigational drug sourced outside the approved framework. We don't recommend that path, but we understand the appeal of the efficacy numbers and we're not going to pretend they don't exist.

Hype gap comparison

Semaglutide: Low hype gap. The enthusiasm is largely justified by the evidence.

Tirzepatide: Low hype gap. The enthusiasm is arguably under-calibrated to the evidence — tirzepatide is better than most users realize.

Retatrutide: High hype gap. The Phase 2 numbers are real, but the jump from "Phase 2 result" to "I should be injecting this" is enormous, and the jump from "injecting the Phase 2 compound" to "injecting whatever this vial contains" is enormous again. Hype is outrunning both evidence and access.

Bottom line

If the question is "which of these should I actually consider using?", the honest answer is: one of the two that are approved, with a prescriber, ideally with insurance coverage. Semaglutide and tirzepatide are approved drugs with strong clinical evidence, and they work.

Retatrutide is a fascinating drug in development. It's not a thing to buy on the internet in 2026. We will update this comparison the day its approval status changes, and we will update the individual compound pages as the ongoing Phase 3 data reads out.